Novocure Net Income From Continuing Ops from 2010 to 2026

NVCR Stock  USD 14.35  0.52  3.50%   
Novocure Net Loss yearly trend continues to be relatively stable with very little volatility. Net Loss is likely to grow to about -144.2 M this year. During the period from 2010 to 2026, Novocure Net Loss destribution of quarterly values had range of 226.9 M from its regression line and mean deviation of  42,544,027. View All Fundamentals
 
Net Loss  
First Reported
2013-12-31
Previous Quarter
-40.1 M
Current Value
-37.3 M
Quarterly Volatility
34.5 M
 
Yuan Drop
 
Covid
Check Novocure financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Novocure's main balance sheet or income statement drivers, such as Depreciation And Amortization of 8.2 M, Interest Expense of 9.2 M or Selling General Administrative of 229.2 M, as well as many indicators such as Price To Sales Ratio of 5.8, Dividend Yield of 0.0 or PTB Ratio of 13.13. Novocure financial statements analysis is a perfect complement when working with Novocure Valuation or Volatility modules.
  
Build AI portfolio with Novocure Stock
Check out the analysis of Novocure Correlation against competitors.
To learn how to invest in Novocure Stock, please use our How to Invest in Novocure guide.

Latest Novocure's Net Income From Continuing Ops Growth Pattern

Below is the plot of the Net Income From Continuing Ops of Novocure over the last few years. It is Novocure's Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Novocure's overall financial position and show how it may be relating to other accounts over time.
Net Income From Continuing Ops10 Years Trend
Slightly volatile
   Net Income From Continuing Ops   
       Timeline  

Novocure Net Income From Continuing Ops Regression Statistics

Arithmetic Mean(92,278,023)
Geometric Mean76,200,621
Coefficient Of Variation(61.12)
Mean Deviation42,544,027
Median(77,370,000)
Standard Deviation56,404,500
Sample Variance3181.5T
Range226.9M
R-Value(0.39)
Mean Square Error2875.2T
R-Squared0.15
Significance0.12
Slope(4,365,431)
Total Sum of Squares50903.5T

Novocure Net Income From Continuing Ops History

2026-144.2 M
2025-151.8 M
2024-168.6 M
2023-207 M
2022-92.5 M
2021-58.4 M
202019.8 M

About Novocure Financial Statements

Novocure shareholders use historical fundamental indicators, such as Net Income From Continuing Ops, to determine how well the company is positioned to perform in the future. Although Novocure investors may analyze each financial statement separately, they are all interrelated. The changes in Novocure's assets and liabilities, for example, are also reflected in the revenues and expenses on on Novocure's income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
Last ReportedProjected for Next Year
Net Loss-151.8 M-144.2 M

Pair Trading with Novocure

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Novocure position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Novocure will appreciate offsetting losses from the drop in the long position's value.

Moving against Novocure Stock

  0.6688656 HOB Biotech GroupPairCorr
  0.58688198 Beijing Balance MedicalPairCorr
  0.55300869 Contec Medical SystemsPairCorr
  0.48300981 Zhonghong Pulin MedicalPairCorr
  0.37IHC Inspiration HealthcarePairCorr
The ability to find closely correlated positions to Novocure could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Novocure when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Novocure - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Novocure to buy it.
The correlation of Novocure is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Novocure moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Novocure moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Novocure can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching

Additional Tools for Novocure Stock Analysis

When running Novocure's price analysis, check to measure Novocure's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Novocure is operating at the current time. Most of Novocure's value examination focuses on studying past and present price action to predict the probability of Novocure's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Novocure's price. Additionally, you may evaluate how the addition of Novocure to your portfolios can decrease your overall portfolio volatility.